|
|
EVA-AMI: Eptifibatide Equal to Abciximab for STEMI Patients Undergoing PCI
|
| Link ID |
350 |
| Title |
EVA-AMI: Eptifibatide Equal to Abciximab for STEMI Patients Undergoing PCI |
| Url |
http://www.medscape.com/viewarticle/565326?src=rss |
| Description |
The results will be reassuring to cath labs already substituting the cheaper GP IIb/IIIa inhibitor in STEMI patients, but at least one expert believes proof of equivalence for two GP IIb/IIIa inhibitors does not answer the question of whether these agents should be widely in use for STEMI patients. Heartwire |
| Category |
Articles > Cardiology |
| Keywords |
|
| Date |
Nov 6, 2007 |
| Contact Name |
|
| Email |
|
Write a Review
Add to My Favorite
Refer it to Friend
Report Broken Link
|
|
Other links at Articles > Cardiology |
| 3. |
FDA and Boston Scientific Recall NexStent Carotid Stent System
|
|
|
The FDA and Boston Scientific announced a class 1 recall of the NexStent Monorail, NexStent carotid stent, and Monorail delivery system, distributed between June 2007 and May 2008, because the tip of the stent-delivery system may detach. Medscape Medical News
|
| 5. |
Childhood Cardiomyopathies: 50% Are Genetic
|
|
|
About half of all children presenting with hypertrophic cardiomyopathy have mutations in exactly the same gene as is seen in adults with the condition, a new study has found. Unexplained hypertrophy in childhood should thus prompt genetic evaluation and analysis of all first-degree relatives where possible, say the researchers. Heartwire
|
|
|
